Jump to content

Control requirements - help needed


galvania

Recommended Posts

Each reagent may have a different requirement -- check the product insert -- but generally, it's a minimum of a positive and negative control on each day of use. ABO reagent QC is optional, since the forward and reverse correlation act as their own QC. We check diluents and potentiators with a negative control as part of our Daily QC.

We define "day of use" as a calander day, from 0001 - 2400.

Link to comment
Share on other sites

I think I should further clarify my question. It is specifically for anti-A, anti-B, and anti-D reagents used for routine typing, as well as the use of a reagent control (ie. like the ctl well in the gel cards). I'm after a specific FDA or AABB requirement. A direct quote would be nice

Link to comment
Share on other sites

Anna,

I looked it up in the 2008 Publications from aabb. The $100 (member price) CFR Mini-handbook which contains the most important portions of the Code of Federal Regulations was in it. ISBN #978-1-56395-258-6. It is a soft cover 512 page book from Sept. 2007.

Hope this helps!

Link to comment
Share on other sites

  • 3 weeks later...

CAP Sept 2007 Checklist:

**REVISED** 10/31/2006

TRM.31400 Phase II N/A YES NO

Do records document acceptable reactivity and specificity of typing sera and reagent cells on each day of use, including a check against known positive and negative cells or antisera, or are manufacturer’s directions for daily quality control followed?

NOTE: Unless manufacturer instructions state otherwise, the following apply:

· Each cell used for antibody detection must be checked each day of use for reactivity of at least one antigen using antisera of 1+ or greater avidity.

· Typing reagents such as anti-D, anti-K, anti-Fy(a), etc., must be checked each day of use.

· Anti-IgG reactivity of antiglobulin reagents may be checked during antibody screening and crossmatching.

· Typing sera and reagent cells must be checked for reactivity and specificity on each day of use, including a check against known positive and negative cells or antisera.

This checklist requirement can be satisfied by testing one vial of each reagent lot each day of testing.

COMMENTARY:

N/A

REFERENCE: Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. Fed Register. 2003(Jan 24):7171 [42CFR493.1217].

AABB Stds BBTS 5.1.3 & 5.1.4 which references FDA 21 CFR 660.20 to 660.28 and FDA Memorandum, March 1992, "Recommended Methods for Blood Grouping Reagents Evaluation" (draft) [Docket No.84S-0181].

Joint Commission CLIA waived testing is covered under PC.16.50.

As previously stated, follow manufacturer's insert. Aceptance criteria for reagents should include review of package insert for revision of standard operating procedures.

We started to use reagent QC as competency assessment tool for all techs on every shift to document for CAP;

TRM.40120 Phase II N/A YES NO

Are control specimens tested in the same manner and by the same personnel as patient samples?

NOTE: It is implicit in quality control (QC) that control specimens are tested in the same manner as patient/client specimens. Moreover, QC specimens must be analyzed by personnel who routinely perform patient/client testing. This does not imply that each operator must perform QC daily, so long as each instrument and/or test system has QC performed at required frequencies, and all analysts participate in QC on a regular basis. To the extent possible, all steps of the testing process must be controlled, recognizing that pre‑analytic and post‑analytic variables may differ from those encountered with patient/clients.

COMMENTARY:

N/A

REFERENCE: Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. Fed Register. 2003(Jan 24):7166 [42CFR493.1256(e)(1)].

Link to comment
Share on other sites

Theoretically, anti-A,-B,-D have to be checked each day of use. Tha anti-A and anti-B only need to be qc'd with a + cell. The anti-D must be checked with a + and neg cell. Also, if your lab does sufficient numbers of ABOs, the front and back types may be used to verify quality performance on that day (you don't have to perform actual QC). You determine what is "sufficient". I have a problem with QC of one bottle of a lot/day. If you are a large BB, you may have multiple racks in use. I believe that each rack should be quality assured, not just the lots. (personal bias).

Link to comment
Share on other sites

This checklist requirement can be satisfied by testing one vial of each reagent lot each day of testing.

For those accredited by the Joint Commission unfortunately this is not true. It is each open vial each day of use.

Standard QC.5.220

The laboratory tests for reactivity the potency and reliability of reagents used for ABO grouping, Rh typing, antibody detection, and compatibility determinations.

Elements of Performance for QC.5.220

1. The laboratory defines its procedures for reactivity testing in writing.

2. Each opened vial of antisera, reactive cells, and reagents is tested for reactivity on each day of use and when a new lot of reagents is first used.

3. The laboratory confirms that each reagent reacts as expected.

4. Results are documented.

Link to comment
Share on other sites

Would choosing one antigen typing sera and testing all 12 cells each day of use be acceptable then?

Thanks Cliff!

My opinion, yes. Otherwise you'd be performing a validation of the panel itself. We use a positive and negative control with each panel we run.
Link to comment
Share on other sites

I vaguely remember -- Man, I'm getting old! -- that my panel's product insert stated that routine QC is not required. It would be difficult to justify, other than merely "to be doing something" to show an inspector, and is horrendiously expensive. Like Daily Reagent QC, it doesn't seem to have much value in determining the quality of reagents.

In addition to a visual inspection, I use the correlation between screen cells and panel as my "panel QC". I expect to see equiavlent reactivity from homozygous and heterozygous cells (Sorry, Dr Judd).

Using expired panel cells in decision-making is a whole different topic ...

Link to comment
Share on other sites

Are I understanding your JCAHO interpertation right, that I need to test each panel cell (all 10 or 12 or 16 or 20 vials) with some antisera (anti-Fya for example) every day I use that panel? What if I pull 3 more selected cells from a 2nd panel. They also need to be tested with the antiserum?

Link to comment
Share on other sites

Each cell used for antibody detection must be checked each day of use for reactivity of at least one antigen using antisera of 1+ or greater avidity.

I believe this is talking about the cells used for antibody screening (antibody detection) as opposed to those used for Antibody Identification.

On CAP surveys, Antibody Detection and Antibody Identification are different things. So I don't believe this address panel cells, only screening cells.

Link to comment
Share on other sites

Here is some of what CLIA says about QC for panels:

§493.1271 Standard: Immunohematology.

(a) Patient testing.

(a)(1) The laboratory must perform ABO grouping, D(Rho) typing, unexpected antibody detection, antibody identification, and compatibility testing by following the manufacturer’s instructions, if provided, and as applicable, 21 CFR 606.151(a) through (e).

Interpretive Guidelines §493.1271(a)(1)

When condition level deficiencies in Immunohematology are in any or all phases of testing, use D5026.

There are no daily quality control requirements for reagent red cell panels used in antibody identification. Panel quality control is a combination of serological test results, such as: strength of reactions and patient phenotype; statistical probability, patient’s medical history; and laboratory standard of practice (i.e., how the laboratory handles compatibility testing for patients with unexpected antibodies). However, the QC requirements pertaining to new batch, lot, shipment of identification systems at §493.1256(e)(1) must be met.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.
  • Advertisement

×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.